Johnson & Johnson announced today that Tremfya (guselkumab) achieved rapid and significant healing of moderate-to-severe scalp psoriasis (PsO), and improved scalp itching and health-related quality of life (HRQoL) outcomes reported by patients.

'Scalp psoriasis is widespread and can present unique challenges in diverse populations. In patients of color, cultural factors related to hair care practices and post-inflammatory pigment changes contribute to the burden of scalp psoriasis', commented Andrew Alexis, Professor of Clinical Dermatology and Vice President for Diversity and Inclusion at Weill Cornell Medicine in New York and lead investigator of the study.

'These findings are critical to expanding our understanding of scalp psoriasis and the role Tremfya can play in treating all patients with this disease', he added.

Copyright (c) 2024 CercleFinance.com. All rights reserved.